Date: 2016-04-14
Type of information: Nomination
Compound:
Company: Merck KGaA (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 14, 2016, Merck KGaA announced the appointment of Maya Martinez-Davis (46), as Global Head of Oncology Franchise for its biopharma business. She will report to Rehan Verjee, Chief Marketing and Strategy Officer of Merck’s Healthcare business sector, and will be based in Billerica, Massachusetts, USA.
In her new role leading the Global Oncology Franchise, Martinez-Davis’responsibilities will include defining integrated global oncology strategies, and delivery of therapeutic launches, starting with avelumab, an investigational antiPD-L1 antibody initially discovered and developed by Merck KGaA , and currently managed under a strategic alliance with Pfizer. The first potential commercial launch for avelumab is expected in 2017.
Prior to joining Merck, Maya Martinez-Davis was a senior executive with Pfizer for more than a decade, delivering on therapeutic area portfolio strategies, in-market growth strategies, and major launches. Prior to her tenure with Pfizer, she held senior-level and director-level positions with Aventis Pharma in oncology.
Financial terms:
Latest news:
